광범위큰B세포림프종에 대한 키메릭항원수용체T세포 (Chimeric Antigen Receptor T-cells) 치료
Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma
채희정, 윤덕현,
소속 상세정보
채희정 ( Chae Hee-Jung )
울산대학교 의과대학 서울아산병원 종양내과
윤덕현 ( Yoon Dok-Hyun )
울산대학교 의과대학 서울아산병원 종양내과
Abstract
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
키워드
B-cell non-Hodgkin lymphoma; Lymphoma, Large B-cell, Diffuse; Chimeric antigen receptor T-cell; CAR-T and immunotherapy
원문 및 링크아웃 정보
등재저널 정보